In the last trading session, 2.67 million Relay Therapeutics Inc (NASDAQ:RLAY) shares changed hands as the company’s beta touched 1.55. With the company’s per share price at $3.51 changed hands at -$0.15 or -4.10% during last session, the market valuation stood at $595.02M. RLAY’s last price was a discount, traded about -205.41% off its 52-week high of $10.72. The share price had its 52-week low at $3.02, which suggests the last value was 13.96% up since then. When we look at Relay Therapeutics Inc’s average trading volume, we note the 10-day average is 2.54 million shares, with the 3-month average coming to 2.25 million.
Analysts gave the Relay Therapeutics Inc (RLAY) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.23. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 2 recommended RLAY as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Relay Therapeutics Inc’s EPS for the current quarter is expected to be -0.51.
Relay Therapeutics Inc (NASDAQ:RLAY) trade information
Instantly RLAY was in red as seen at the end of in last trading. With action 7.34%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -14.81%, with the 5-day performance at 7.34% in the green. However, in the 30-day time frame, Relay Therapeutics Inc (NASDAQ:RLAY) is -11.36% down. Looking at the short shares, we see there were 16.19 million shares sold at short interest cover period of 10.69 days.
The consensus price target for the stock as assigned by Wall Street analysts is 19, meaning bulls need an upside of 81.53% from its current market value. According to analyst projections, RLAY’s forecast low is 16 with 25 as the target high. To hit the forecast high, the stock’s price needs a -612.25% plunge from its current level, while the stock would need to soar -355.84% for it to hit the projected low.
Relay Therapeutics Inc (RLAY) estimates and forecasts
Year-over-year growth is forecast to reach -61.36% down from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 11.11k. 8 analysts are of the opinion that Relay Therapeutics Inc’s revenue for the current quarter will be 3.76M. The company’s revenue for the corresponding quarters a year ago was 10.01M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -99.89%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -23.05%. The 2025 estimates are for Relay Therapeutics Inc earnings to increase by 2.79%, but the outlook for the next 5-year period is at 0.41% per year.
RLAY Dividends
Relay Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Feb-25.
Relay Therapeutics Inc (NASDAQ:RLAY)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.80% of Relay Therapeutics Inc shares while 99.33% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 101.15%. There are 99.33% institutions holding the Relay Therapeutics Inc stock share, with SB INVESTMENT ADVISERS (UK) LTD the top institutional holder. As of 2024-06-30, the company held 21.0093% of the shares, roughly 27.9 million RLAY shares worth $181.94 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 8.8125% or 11.7 million shares worth $76.32 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund . With 4.86 shares estimated at $17.05 million under it, the former controlled 2.87% of total outstanding shares. On the other hand, Vanguard Small-Cap Index Fund held about 2.39% of the shares, roughly 4.05 shares worth around $14.22 million.
